Hepatocellular Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Brazilian Reality of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma; Hepatocellular Carcinoma by BCLC Stage; Hepatocellular Carcinoma Stage I; Hepatocellular Carcinoma Stage II; Hepatocellular Carcinoma Stage III Sponsors: Hospital Israelita Albert Einstein; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials

SHEPHERD(SHort-acting Embolization Particles for Patients With HEpatocellular Carcinoma Treated by RaDioembolization)
Conditions: Hepatocellular Carcinoma Interventions: Device: NexGel Sponsors: Next Biomedical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Conditions: Lung Cancer, Non-small Cell; Lung Cancer Metastatic; Solid Tumor, Adult; Advanced Cancer; Lung Cancer, Small Cell; Metastatic Colorectal Cancer; Metastatic Renal Cell Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic Sarcoma; Metastatic Osteosarcoma Interventions: Biological: KB707 Sponsors: Krystal Biotech, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials

Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation
Conditions: Hepatocellular Carcinoma Interventions: Radiation: Stereotactic Body Radiotherapy (SBRT) Sponsors: Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
Conditions: Hepatocellular Carcinoma Interventions: Biological: Peptide-based hepatocellular carcinoma vaccine IMA970A; Combination Product: Durvalumab; Other: Montanide (Adjuvant) Sponsors: National Cancer Institute, Naples Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2024 Category: Research Source Type: clinical trials

A Phase II, Single-arm, Multicenter, Prospective Study of Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
Conditions: Cadonilimab and Lenvatinib Interventions: Drug: Cadonilimab lenvatinib Sponsors: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials

Study of NP-101 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Undergoing Y-90 Treatment
Conditions: Hepatocellular Carcinoma Interventions: Drug: NP-101 Sponsors: University of Florida; Novatek Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 22, 2024 Category: Research Source Type: clinical trials

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)
Conditions: Hepatocellular Carcinoma With PVTT Interventions: Drug: Tislelizumab; Drug: Lenvatinib Sponsors: Li Xiao Wei Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2024 Category: Research Source Type: clinical trials

BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
Conditions: Solid Tumors; Non Small Cell Lung Cancer; Hepatocellular Carcinoma Interventions: Drug: BI-1910; Drug: Pembrolizumab Sponsors: BioInvent International AB Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials

A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
Conditions: Carcinoma, Hepatocellular Interventions: Other: Immunotherapy, targeted therapy. Sponsors: Qianfoshan Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials

Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
Conditions: Hepatocellular Carcinoma; Narrow Margin; Radiotherapy Interventions: Radiation: Adjuvant SIB radiotherapy Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials

Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery
Conditions: Hepatocellular Carcinoma; Neuroendocrine Tumors With Bilobar Hepatic Tumors Interventions: Device: TACE Catheters Sponsors: Abramson Cancer Center at Penn Medicine; TriSalus Life Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials

ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery
Conditions: Hepatocellular Carcinoma Interventions: Drug: RD-Cy7 fluorophore Sponsors: Institute of Automation, Chinese Academy of Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials

FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Conditions: Hepatocellular Carcinoma Interventions: Procedure: Hepatic arterial infusion chemotherapy; Drug: Lenvatinib; Drug: Toripalimab; Drug: oxaliplatin , fluorouracil, and leucovorin Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 11, 2024 Category: Research Source Type: clinical trials

Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With Transarterial Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Real-World Study
Conditions: Hepatocellular Carcinoma Interventions: Drug: Atezolizumab combined with Bevacizumab; Drug: Sintilimab combined with Bevacizumab; Procedure: Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy Sponsors: Sun Yat-sen University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2024 Category: Research Source Type: clinical trials